MST Continus

Morphine Sulfate

Method of action: Analgesic, Antitussive, Hypnotic, Opioid

Treatment option: Pain, Shock

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of MST Continus

As an Opioid Analgesic, MST Continus is a single-ingredient, oral modified-release tablet containing Morphine Sulfate as its active substance. It is designed to provide long-acting pain relief by slowly releasing the medication over an extended period.

Property	Description
Active ingredient	Morphine Sulfate
Form	Modified-release tablet (Oral solid dosage form)
Pharmacological class	Opioid Analgesic
Common use	Continuous, around-the-clock pain management
Origin	Semi-synthetic (derived from natural opium alkaloids)

What Type of Medicine is MST Continus?

MST Continus is a medicine whose active ingredient is Morphine Sulfate, classified as a potent Opioid Analgesic, and formulated as an oral modified-release tablet. This compound is categorized as a derivative of natural opium alkaloids meaning the active substance is chemically refined from the opium poppy plant. It is clinically recognized for its high potency in pain relief, establishing it as a primary tool within its pharmacological class. The product's distinctive identity lies in its prolonged-release formulation, a key differentiating factor that employs a specialized polymer matrix engineered to control the rate at which the active ingredient is released into the body, offering a smoother profile compared to immediate-release forms of the same substance. This design specifically targets the need for sustained systemic effect.

Why is MST Continus Used for Pain Relief?

The primary purpose of MST Continus is to provide continuous, steady pain management for moderate to severe pain that requires treatment over an extended period. The controlled-release design is integral to this purpose, as pharmacological studies confirm that the formulation ensures the Morphine Sulfate maintains a consistent analgesic effect throughout the day and night. This prolonged, stable release prevents the fluctuations in pain intensity that can occur when shorter-acting medications wear off. By modulating pain signals within the central nervous system, this oral solid dosage form provides necessary, sustained relief for patients requiring around-the-clock control, representing a typical use scenario for chronic, persistent pain.

Regulatory References

NIH MedlinePlus Drug Information

What side effects are possible with MST Continus?

Possible Side Effects and Safety Information

The safety profile for MST Continus (Morphine Sulfate modified-release tablets) is officially classified by government regulatory authorities, detailing potential adverse reactions by frequency and affected body system.

Documented Adverse Reactions

The most frequently reported adverse effects often involve the central nervous system (CNS) and the gastrointestinal system. The regulatory classification for adverse reactions is organized as follows:

Very Common Reactions: These are reactions that may affect more than 1 in 10 individuals and include constipation, nausea, and vomiting. Nausea and vomiting are noted to be more common at the beginning of treatment.
Common Reactions: These may affect up to 1 in 10 individuals and include dizziness, somnolence (drowsiness), headache, dry mouth, pruritus (itching), and excessive sweating (hyperhidrosis).
Uncommon Reactions: These may affect up to 1 in 100 individuals and include states of confusion, hallucinations, and urinary retention.

Serious Adverse Reactions and Safety Constraints

Official prescribing information identifies several serious adverse reactions. The most critical is severe respiratory depression, which is a potentially life-threatening event. Other serious documented reactions include circulatory depression and paralytic ileus.

Since this medication is an opioid, continuous use carries a risk for the development of tolerance and physical dependence. The risk of these effects increases with the duration of exposure.

Safety notes for specific populations exist, including those with renal or hepatic impairment, where there is a risk of the active substance accumulating. Older adults may also exhibit increased sensitivity to the medication’s effects.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

The most significant hazard of an overdose with MST Continus is life-threatening respiratory depression, as documented in prescribing information. Overdose manifestations include progressive profound CNS depression, which can range from excessive somnolence and stupor to coma and the cessation of breathing (apnea). Other documented signs of opioid toxicity are miosis (pinpoint pupils), severe hypotension, and signs of oxygen deprivation such as cyanosis and cold, clammy skin.

Accidental ingestion, especially by a child, is explicitly identified in regulatory documents as a circumstance that can result in a fatal overdose, requiring immediate action. Patients with underlying renal or hepatic impairment may also be at higher risk for a prolonged effect and cumulative toxicity.

Required Emergency Actions

Official labeling mandates that immediate medical attention must be sought for any suspected overdose. The required emergency management involves securing the airway and administering the opioid antagonist Naloxone, which is documented as the antidote. Treatment procedures emphasize symptomatic and supportive treatment, including continuous monitoring of vital signs and observation for recurrent respiratory depression.

Therapeutic Uses of MST Continus

MST Continus is commonly used for the management of severe and persistent pain that generally requires continuous, around-the-clock opioid support. This medication is typically reserved for conditions presenting with systemic or localized discomfort where additional symptomatic support is needed.

Treating Severe, Persistent Pain

MST Continus is commonly used for managing symptoms that create noticeable physiological strain, such as the severe pain associated with chronic illnesses, including advanced cancer, or high-need post-operative recovery. It is relevant when supportive symptom management is appropriate for pain manifestations that are difficult to manage.

Providing Sustained, Around-the-Clock Relief

The medication is relevant for easing symptoms related to persistent discomfort across the full day and night. This supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load when symptoms are more noticeable, and may assist with managing symptoms associated with episodic or fluctuating changes.

Foundational Use in Therapeutic Escalation

This medication is considered relevant in clinical settings that involve acute or unstable symptom patterns, serving as a foundational treatment where pain symptoms remain intractable or severe despite the use of treatments that require additional support. It supports the patient in maintaining functional comfort by providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Support for Persistent Discomfort
Primary focus: Management of around-the-clock symptom patterns.
Symptom duration: Applied for management of long-term symptom domains.
Typical use context: Therapeutic escalation when less potent treatments require additional support.

Eligibility and Restrictions for Use

MST Continus eligibility is strictly defined by regulatory guidelines based on age and underlying health conditions.

Contraindicated Populations

Use is prohibited for individuals with hypersensitivity to morphine, known or suspected paralytic ileus or other gastrointestinal obstruction, and those with significant respiratory depression or severe asthma. The medicine is contraindicated in children under one year of age and in patients taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping them. It is also prohibited in patients with acute hepatic disease.

Conditional and Restricted Use

Special caution is required for patients with severely impaired renal or hepatic function, as a dosage reduction may be necessary. For older adults, the label advises a possible dose reduction. High-strength tablets (e.g., 100 mg and 200 mg) are strictly restricted only to patients in whom opioid tolerance has been established. The medicine is not recommended in the immediate post-operative period.

Pregnancy and Lactation Status

Use during pregnancy may cause fetal harm, and prolonged use can result in Neonatal Opioid Withdrawal Syndrome. Lactation is not recommended due to the presence of morphine in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of MST Continus by defining substances that pose a risk through pharmacodynamic synergism, pharmacokinetic modification, or mandatory administration separation.

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated and strictly requires a 14-day period after MAOI discontinuation before initiating treatment.

Documented Interaction Patterns

The most clinically relevant interaction involves Central Nervous System (CNS) Depressants, including benzodiazepines, sedatives, and other opioids. This combination creates pharmacodynamic synergism that may lead to profound sedation and severe respiratory depression.

Consumption of alcohol is restricted due to a formulation-specific pharmacokinetic risk. Alcohol may cause the modified-release tablet to rapidly release the active substance (dose dumping), resulting in potentially fatal high plasma concentrations.

Interaction Type	Interacting Substance(s)	Official Outcome
Metabolic Inhibition	Cimetidine	Increases morphine exposure.
Metabolic Induction	Rifampicin, Ritonavir	Decreases plasma morphine concentrations.
Serotonergic Risk	Serotonergic Drugs	Potential for Serotonin Syndrome.

In specific populations, such as those with renal or severe hepatic impairment, official labeling notes that the clearance of morphine and its active metabolites is decreased, resulting in altered exposure.

Mechanism of Action

How MST Continus Works

MST Continus is a sustained-release formulation of morphine sulfate. Its action is centered on the central nervous system (CNS) and is defined by the selective engagement with key membrane-bound receptors.

Modulation of Opioid Receptor Signaling

Morphine acts primarily as a full agonist at mu-opioid receptors (mathrmMOR), but also exhibits activity at kappa- and delta-opioid receptors. Binding to these G-protein coupled receptors (GPCRs) initiates an intracellular cascade that results in the inhibition of adenylyl cyclase. This leads to a reduction in cyclic AMP (cAMP) and the subsequent hyperpolarization of the neuronal membrane via potassium efflux, ultimately reducing neuronal excitability.

Influence on Signal Transmission

Its mechanistic consequence includes the pre-synaptic suppression of neurotransmitter release—specifically inhibitory modulation of calcium channel function that reduces the exocytosis of excitatory transmitters like Substance P and glutamate from primary afferent neurons. The extended-release formulation sustains this effect, leading to the modulation of nociceptive signal propagation across the spinal cord and brainstem.

Dosage and Administration Information

How to Use MST Continus

MST Continus is administered as an oral modified-release tablet, and its usage protocol is specifically structured to provide continuous analgesic support on a fixed schedule. The design of the prolonged-release tablet mandates that it must be swallowed whole and must not be broken, crushed, chewed, or dissolved. This ensures the Morphine Sulfate is released slowly over the 12-hour dosing interval, as outlined in official prescribing information.

The medication is used according to a fixed 12-hourly dosing schedule (twice daily). For opioid-naïve adult patients, the starting regimen is typically 30 mg every 12 hours for those over 70 kg, or 20 mg every 12 hours for patients under 70 kg. Dosage must then be individually adjusted, or titrated, often in 30% to 50% increments, until the required effect is sustained across the full 12-hour period.

Official Administration Guidelines

Instruction	Detail
Route of Administration	Oral (swallowing the prolonged-release tablet).
Dosing Schedule	Fixed 12-hourly intervals (twice daily).
Preparation Requirements	Must be swallowed whole; must not be broken, chewed, crushed, or dissolved.
Age-Group Rules	Dose reduction may be advisable in older adults. Pediatric dosing uses a milligram-per-kilogram calculation.
Discontinuation	Requires the dose to be gradually reduced over time to avoid abstinence symptoms.

This medication is not generally used in the immediate post-operative period (first 24 hours) or until normal bowel function is assured. The overall protocol emphasizes maintaining the 12-hour integrity of the dose through proper administration and individualizing the regimen through careful titration.

Recent Clinical Evidence

Research evidence / Overview of studies for MST Continus

Evidence for Continuous Management of Severe and Persistent Pain

Studies of the modified-release formulation of morphine sulfate were conducted in contexts involving pain that requires continuous, around-the-clock opioid support. This research was applied in studies examining patient-reported experiences in conditions characterized by persistent symptoms, such as severe pain associated with chronic illnesses, including cancer pain, and certain types of chronic non-cancer pain (CNCP). The evidence primarily comes from Randomized Controlled Trials (RCTs) and systematic reviews.

Researchers tracked outcomes related to physical discomfort, often using patient-reported scales to track pain intensity. Studies also tracked the frequency of use of supplemental pain relief to determine how the controlled-release formula was observed in research exploring episodic changes. Bioequivalence studies were conducted to examine the drug's absorption and distribution profile, and research describes the pharmacokinetic patterns related to the prolonged-release action.

Long-term Studies and Follow-up Data

Studies explored outcomes beyond the initial acute phase, tracking outcomes related to systemic or functional imbalance and daily functioning or activity level. Most pivotal RCTs follow-up durations were limited, often running for only a few weeks to assess core parameters in non-cancer pain settings.

Findings describe patterns observed in the studies related to changes measured during the study period, with some evidence indicating that treatment was associated with changes in certain aspects of cognitive functioning. However, long-term effects on consistent functional status and quality of life are not fully established across the entire body of evidence.

What Research is Still Developing or Uncertain

Research contributes to the broader evidence landscape, but some areas of uncertainty remain. A key limitation is the short follow-up durations in many core randomized trials. Studies often report high rates of patient attrition (dropouts) in long-term oral opioid trials, which may make it difficult to draw definitive conclusions about sustained outcomes. While research provides insight into short-term changes, findings were mixed or inconclusive in systematic reviews regarding consistent, long-term outcomes reflecting daily functioning or activity level across all patient groups.

Key Studies & References Morphine Extended-Release Oral Capsule and Tablet (NIH MedlinePlus Drug Information)

Frequently Asked Questions (FAQ)

Common questions about MST Continus (FAQ)

Q: How should I store this medication?

Official regulatory documents advise that this medication should be stored at room temperature, typically between 68 F to 77 F (20 C to 25 C). Official information recommends keeping the product in its original, tightly closed container and storing it out of the sight and reach of children.

Q: Can I drink alcohol while taking this medicine?

Some official product information may not list a specific contraindication (a reason not to take the medicine) between this product and alcohol. Generally, patients are encouraged to follow established health guidelines for alcohol use. For specific concerns about combining the medication with alcohol, consultation with a healthcare professional is recommended.

Q: Does it make you sleepy or affect your mood?

Regulatory documents indicate that this medicine can be associated with side effects related to the nervous system and psychiatric disorders. These effects may include dizziness, headache, nervousness, and in rare instances, psychosis or suicidal behavior. If any changes in mood or thinking are experienced, seeking guidance from a healthcare professional is important.

Q: Is this safe for children 2 years old?

Official safety information states that this medication is generally not recommended for long-term therapy in children. Furthermore, it is contraindicated (should not be used) in children under 6 years of age for some indications, as children can be particularly sensitive to the toxic effects of this type of compound (4-aminoquinoline). The use of this medication in children requires professional guidance from a healthcare provider.

Q: What should I know about taking this while pregnant?

Official product information notes that this medication crosses the placenta. Although data on its use during pregnancy is limited, official prescribing information notes that in specific high-risk situations, the benefit of the medication is sometimes judged by the prescriber to outweigh the potential risk to the fetus. It has been recommended for pregnant patients with certain autoimmune diseases.

Q: How should I take this (e.g., with food)?

According to official administration instructions, the tablets should be swallowed whole with a liquid. Official administration instructions specify that the product is typically taken at mealtimes or with a glass of milk.

How should MST Continus be stored and disposed of?

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Do not store the tablets above 25°C (77°F).
Container	Must be kept in the original container (e.g., blister pack) to maintain product integrity.
Safety	Store this opioid medicine out of the sight and reach of children due to the risk of accidental overdose.
Expiry	Do not use the medicine after the expiry date printed on the packaging.

Disposal Instructions

Official disposal is required according to local regulations. Environmental restrictions state the product should not be discarded via wastewater or general household trash. For unused or expired opioids, health authorities recommend using authorized drug take-back programs as the preferred method to prevent misuse. If take-back is not available, official guidance suggests mixing the drug with an undesirable substance (e.g., coffee grounds) and sealing it before discarding in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.